Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
SCLN's Cash to Debt is ranked higher than
98% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. SCLN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SCLN' s 10-Year Cash to Debt Range
Min: 2.83  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.82
SCLN's Equity to Asset is ranked higher than
82% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. SCLN: 0.82 )
Ranked among companies with meaningful Equity to Asset only.
SCLN' s 10-Year Equity to Asset Range
Min: 0.52  Med: 0.83 Max: 0.93
Current: 0.82
0.52
0.93
Interest Coverage 541.33
SCLN's Interest Coverage is ranked lower than
53% of the 390 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2854.00 vs. SCLN: 541.33 )
Ranked among companies with meaningful Interest Coverage only.
SCLN' s 10-Year Interest Coverage Range
Min: 34.65  Med: 541.33 Max: 9999.99
Current: 541.33
34.65
9999.99
F-Score: 6
Z-Score: 7.41
M-Score: -2.80
WACC vs ROIC
18.05%
23.37%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 11.08
SCLN's Operating margin (%) is ranked higher than
60% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. SCLN: 11.08 )
Ranked among companies with meaningful Operating margin (%) only.
SCLN' s 10-Year Operating margin (%) Range
Min: -6000  Med: -28.90 Max: 26.31
Current: 11.08
-6000
26.31
Net-margin (%) 11.12
SCLN's Net-margin (%) is ranked higher than
68% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. SCLN: 11.12 )
Ranked among companies with meaningful Net-margin (%) only.
SCLN' s 10-Year Net-margin (%) Range
Min: -4933.33  Med: -21.53 Max: 24.77
Current: 11.12
-4933.33
24.77
ROE (%) 10.32
SCLN's ROE (%) is ranked higher than
60% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. SCLN: 10.32 )
Ranked among companies with meaningful ROE (%) only.
SCLN' s 10-Year ROE (%) Range
Min: -211.35  Med: -14.53 Max: 30.21
Current: 10.32
-211.35
30.21
ROA (%) 8.86
SCLN's ROA (%) is ranked higher than
72% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. SCLN: 8.86 )
Ranked among companies with meaningful ROA (%) only.
SCLN' s 10-Year ROA (%) Range
Min: -136.57  Med: -11.94 Max: 25.6
Current: 8.86
-136.57
25.6
ROC (Joel Greenblatt) (%) 61.60
SCLN's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. SCLN: 61.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SCLN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -706.12  Med: -85.76 Max: 99.43
Current: 61.6
-706.12
99.43
Revenue Growth (3Y)(%) 3.50
SCLN's Revenue Growth (3Y)(%) is ranked lower than
59% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. SCLN: 3.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SCLN' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.7  Med: 20.10 Max: 125.7
Current: 3.5
-4.7
125.7
EBITDA Growth (3Y)(%) -2.40
SCLN's EBITDA Growth (3Y)(%) is ranked lower than
62% of the 494 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. SCLN: -2.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SCLN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -53.8  Med: -8.35 Max: 13.5
Current: -2.4
-53.8
13.5
EPS Growth (3Y)(%) -0.70
SCLN's EPS Growth (3Y)(%) is ranked lower than
58% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. SCLN: -0.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SCLN' s 10-Year EPS Growth (3Y)(%) Range
Min: -58.7  Med: -5.25 Max: 132.1
Current: -0.7
-58.7
132.1
» SCLN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

SCLN Guru Trades in Q3 2014

Paul Tudor Jones 42,053 sh (New)
Chuck Royce 5,000 sh (-66.89%)
Jim Simons 85,900 sh (-73.27%)
» More
Q4 2014

SCLN Guru Trades in Q4 2014

Jim Simons 199,420 sh (+132.15%)
Chuck Royce 5,000 sh (unchged)
Paul Tudor Jones 41,174 sh (-2.09%)
» More
Q1 2015

SCLN Guru Trades in Q1 2015

Jim Simons 440,400 sh (+120.84%)
Chuck Royce 5,000 sh (unchged)
Paul Tudor Jones 35,055 sh (-14.86%)
» More
Q2 2015

SCLN Guru Trades in Q2 2015

Jim Simons 691,660 sh (+57.05%)
Chuck Royce 5,000 sh (unchged)
Paul Tudor Jones 28,310 sh (-19.24%)
» More
» Details

Insider Trades

Latest Guru Trades with SCLN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.63
SCLN's P/E(ttm) is ranked higher than
62% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.60 vs. SCLN: 25.63 )
Ranked among companies with meaningful P/E(ttm) only.
SCLN' s 10-Year P/E(ttm) Range
Min: 6.29  Med: 16.56 Max: 189.41
Current: 25.63
6.29
189.41
Forward P/E 13.66
SCLN's Forward P/E is ranked higher than
80% of the 232 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.47 vs. SCLN: 13.66 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.10
SCLN's PE(NRI) is ranked higher than
63% of the 478 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. SCLN: 25.10 )
Ranked among companies with meaningful PE(NRI) only.
SCLN' s 10-Year PE(NRI) Range
Min: 6.32  Med: 16.48 Max: 280
Current: 25.1
6.32
280
P/B 2.46
SCLN's P/B is ranked higher than
60% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. SCLN: 2.46 )
Ranked among companies with meaningful P/B only.
SCLN' s 10-Year P/B Range
Min: 0.82  Med: 2.12 Max: 6.15
Current: 2.46
0.82
6.15
P/S 2.77
SCLN's P/S is ranked higher than
54% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. SCLN: 2.77 )
Ranked among companies with meaningful P/S only.
SCLN' s 10-Year P/S Range
Min: 0.67  Med: 2.43 Max: 12.41
Current: 2.77
0.67
12.41
PFCF 12.89
SCLN's PFCF is ranked higher than
89% of the 274 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.71 vs. SCLN: 12.89 )
Ranked among companies with meaningful PFCF only.
SCLN' s 10-Year PFCF Range
Min: 3.83  Med: 15.42 Max: 458
Current: 12.89
3.83
458
POCF 12.08
SCLN's POCF is ranked higher than
82% of the 393 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.63 vs. SCLN: 12.08 )
Ranked among companies with meaningful POCF only.
SCLN' s 10-Year POCF Range
Min: 3.76  Med: 14.58 Max: 458
Current: 12.08
3.76
458
EV-to-EBIT 18.16
SCLN's EV-to-EBIT is ranked higher than
62% of the 491 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.81 vs. SCLN: 18.16 )
Ranked among companies with meaningful EV-to-EBIT only.
SCLN' s 10-Year EV-to-EBIT Range
Min: -24.6  Med: 3.65 Max: 207.3
Current: 18.16
-24.6
207.3
Shiller P/E 23.28
SCLN's Shiller P/E is ranked higher than
68% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.72 vs. SCLN: 23.28 )
Ranked among companies with meaningful Shiller P/E only.
SCLN' s 10-Year Shiller P/E Range
Min: 15.13  Med: 27.58 Max: 218.5
Current: 23.28
15.13
218.5
Current Ratio 4.16
SCLN's Current Ratio is ranked higher than
74% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. SCLN: 4.16 )
Ranked among companies with meaningful Current Ratio only.
SCLN' s 10-Year Current Ratio Range
Min: 1.32  Med: 5.67 Max: 12.05
Current: 4.16
1.32
12.05
Quick Ratio 3.81
SCLN's Quick Ratio is ranked higher than
74% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. SCLN: 3.81 )
Ranked among companies with meaningful Quick Ratio only.
SCLN' s 10-Year Quick Ratio Range
Min: 1.05  Med: 5.22 Max: 11.4
Current: 3.81
1.05
11.4
Days Inventory 191.26
SCLN's Days Inventory is ranked lower than
81% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. SCLN: 191.26 )
Ranked among companies with meaningful Days Inventory only.
SCLN' s 10-Year Days Inventory Range
Min: 171.31  Med: 265.07 Max: 2281.25
Current: 191.26
171.31
2281.25
Days Sales Outstanding 93.96
SCLN's Days Sales Outstanding is ranked lower than
65% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. SCLN: 93.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCLN' s 10-Year Days Sales Outstanding Range
Min: 80.45  Med: 124.79 Max: 232.02
Current: 93.96
80.45
232.02

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.83
SCLN's Price/Net Cash is ranked higher than
66% of the 175 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.86 vs. SCLN: 6.83 )
Ranked among companies with meaningful Price/Net Cash only.
SCLN' s 10-Year Price/Net Cash Range
Min: 2.06  Med: 5.51 Max: 343.8
Current: 6.83
2.06
343.8
Price/Net Current Asset Value 3.56
SCLN's Price/Net Current Asset Value is ranked higher than
76% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. SCLN: 3.56 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SCLN' s 10-Year Price/Net Current Asset Value Range
Min: 0.93  Med: 3.84 Max: 53.57
Current: 3.56
0.93
53.57
Price/Tangible Book 3.13
SCLN's Price/Tangible Book is ranked higher than
55% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. SCLN: 3.13 )
Ranked among companies with meaningful Price/Tangible Book only.
SCLN' s 10-Year Price/Tangible Book Range
Min: 0.84  Med: 3.52 Max: 17.88
Current: 3.13
0.84
17.88
Price/Projected FCF 0.95
SCLN's Price/Projected FCF is ranked higher than
90% of the 319 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.70 vs. SCLN: 0.95 )
Ranked among companies with meaningful Price/Projected FCF only.
SCLN' s 10-Year Price/Projected FCF Range
Min: 0.69  Med: 1.19 Max: 6.05
Current: 0.95
0.69
6.05
Price/Median PS Value 1.14
SCLN's Price/Median PS Value is ranked higher than
59% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. SCLN: 1.14 )
Ranked among companies with meaningful Price/Median PS Value only.
SCLN' s 10-Year Price/Median PS Value Range
Min: 0.26  Med: 1.90 Max: 138.75
Current: 1.14
0.26
138.75
Price/Graham Number 1.83
SCLN's Price/Graham Number is ranked higher than
61% of the 360 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. SCLN: 1.83 )
Ranked among companies with meaningful Price/Graham Number only.
SCLN' s 10-Year Price/Graham Number Range
Min: 0.68  Med: 1.49 Max: 4.95
Current: 1.83
0.68
4.95
Earnings Yield (Greenblatt) (%) 5.53
SCLN's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. SCLN: 5.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SCLN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.5  Med: 11.20 Max: 482.2
Current: 5.53
0.5
482.2

Analyst Estimate

Dec15
Revenue(Mil) 154
EPS($) 0.57
EPS without NRI($) 0.57

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:SPJ.Germany,
SciClone Pharmaceuticals Inc is a Delaware corporation was incorporated in 1990. The Company is a specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders. The Company's primary product, ZADAXIN (thymalfasin) is approved in over 30 countries and may be used for the treatment of HBV, HCV, and certain cancers, and as a vaccine adjuvant according to the local regulatory approvals. It markets approximately 7 partnered and in-licensed products in China, including Aggrastat, an interventional cardiology product. The Company operates is two segments based on the nature and locations of its customers: China and the rest of the world which includes its US and Hong Kong operations. The Company sells ZADAXIN in various international markets through its wholly owned subsidiary, SciClone Pharmaceuticals International Ltd. SPIL orders ZADAXIN from its European manufacturer and contracts with a third party for the storage of its finished goods inventory at warehousing facilities in Hong Kong. SPIL then distributes its product from these warehousing facilities based on purchase orders from its customers. ZADAXIN is manufactured in Europe by third parties under exclusive contract manufacturing and supply agreements. Its competitors include pharmaceutical companies, biotechnology firms, universities and other research institutions, in the US, China and other territories, that are actively engaged in research and development or marketing of products in the therapeutic areas the Company is pursuing. The Company's products in clinical development in the US, China and other foreign countries are subject to approval by the FDA, the SFDA and similar regulatory authorities.
» More Articles for SCLN

Headlines

Articles On GuruFocus.com
SciClone to Present at Needham Healthcare Conference on April 14, 2015 Apr 06 2015 
Profits in Motion: SciClone Pharmaceuticals (SCLN), Omega Protein (OME), Zoe's Kitchen (ZOES) Mar 12 2015 
SciClone to Present at BIO CEO & Investor Conference on February 9, 2015 Jan 28 2015 
SciClone Provides 2014 Financial Update and 2015 Revenue Guidance Jan 06 2015 
SciClone to Present at Jefferies Global Healthcare Conference on November 19th Nov 06 2014 
SciClone Pharmaceuticals to Report Financial Results for the Third Quarter 2014 on November 10th Oct 30 2014 
Weekly CFO Sells Highlight: V, SCLN, VR, AMSG Jun 25 2012 
comment on SCLN Apr 29 2012 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-K/A) Dec 06 2010 
SciClone Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 

More From Other Websites
SciClone To Present At Two Investor Conferences On September 10, 2015 Aug 27 2015
SciClone To Present At Two Investor Conferences On September 10, 2015 Aug 27 2015
SCICLONE PHARMACEUTICALS INC Financials Aug 21 2015
10-Q for SciClone Pharmaceuticals, Inc. Aug 12 2015
Theravance Biopharma Posts Narrower Q2 Loss, View Revised - Analyst Blog Aug 11 2015
Edited Transcript of SCLN earnings conference call or presentation 10-Aug-15 8:30pm GMT Aug 10 2015
SciClone reports 2Q loss Aug 10 2015
SciClone reports 2Q loss Aug 10 2015
SciClone Reports Second Quarter 2015 Financial Results Aug 10 2015
SciClone Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Aug 10 2015
SCICLONE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 10 2015
SciClone Reports Second Quarter 2015 Financial Results Aug 10 2015
Q2 2015 SciClone Pharmaceuticals Inc Earnings Release - After Market Close Aug 10 2015
Cancer Prevention Pharmaceuticals, Inc. Announces Appointment of Jon S. Saxe to its Board of... Jul 23 2015
SciClone Pharmaceuticals To Report Financial Results For The Second Quarter 2015 On August 10th Jul 23 2015
SciClone Pharmaceuticals To Report Financial Results For The Second Quarter 2015 On August 10th Jul 23 2015
3 Reasons SciClone Pharmaceuticals (SCLN) is a Great Value Stock - Tale of the Tape Jul 20 2015
SciClone Shoots Out of Base, Phibro Turns Tail Jul 01 2015
Should You Buy Surging SciClone Pharmaceuticals (SCLN), Up By 14.66% Today? Jul 01 2015
Edited Transcript of SCLN presentation 3-Jun-15 2:30pm GMT Jun 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK